Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Tenenbaum

Showing results (111-120 of 116) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 116 results.
Atherosclerosis|September 15, 2006
Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetesHelena Tenenbaum, Solomon Behar, Valentina Boyko, et al.
American Heart Journal|March 27, 2007
Insulin resistance is associated with increased risk of major cardiovascular events in patients with preexisting coronary artery diseaseAlexander Tenenbaum, Yehuda Adler, Valentina Boyko, et al.
Cardiovascular Diabetology|September 16, 2015
Impaired fasting glucose and left ventricular diastolic dysfunction in middle-age adults: a retrospective cross-sectional analysis of 2971 subjectsAssi Milwidsky, Elad Maor, Shaye Kivity, et al.
Cardiovascular Diabetology|August 16, 2017
Admission blood glucose and 10-year mortality among patients with or without pre-existing diabetes mellitus hospitalized with heart failureOsnat Itzhaki Ben Zadok, Ran Kornowski, Ilan Goldenberg, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 30, 2006
Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin levelAki Hiuge, Alexander Tenenbaum, Norikazu Maeda, et al.
Cardiovascular Diabetology|June 6, 2019
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) FoundationJean-Charles Fruchart, Raul D Santos, Carlos Aguilar-Salinas, et al.
Pageof 12

Showing results (111-120 of 116) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 116 results.
Atherosclerosis|September 15, 2006
Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetesHelena Tenenbaum, Solomon Behar, Valentina Boyko, et al.
American Heart Journal|March 27, 2007
Insulin resistance is associated with increased risk of major cardiovascular events in patients with preexisting coronary artery diseaseAlexander Tenenbaum, Yehuda Adler, Valentina Boyko, et al.
Cardiovascular Diabetology|September 16, 2015
Impaired fasting glucose and left ventricular diastolic dysfunction in middle-age adults: a retrospective cross-sectional analysis of 2971 subjectsAssi Milwidsky, Elad Maor, Shaye Kivity, et al.
Cardiovascular Diabetology|August 16, 2017
Admission blood glucose and 10-year mortality among patients with or without pre-existing diabetes mellitus hospitalized with heart failureOsnat Itzhaki Ben Zadok, Ran Kornowski, Ilan Goldenberg, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 30, 2006
Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin levelAki Hiuge, Alexander Tenenbaum, Norikazu Maeda, et al.
Cardiovascular Diabetology|June 6, 2019
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) FoundationJean-Charles Fruchart, Raul D Santos, Carlos Aguilar-Salinas, et al.
Pageof 12